Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018

  • ID: 4576065
  • Report
  • 123 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • ConverGene LLC
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Nuevolution AB
  • Red Glead Discovery AB
  • MORE
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2018

Summary:

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 4, 19 and 4 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Respiratory which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Multiple Myeloma (Kahler Disease), Diffuse Large B-Cell Lymphoma, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Leukemias, Myelodysplastic Syndrome, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Atopic Dermatitis, Colorectal Cancer, Follicular Lymphoma, Hematological Tumor, Inflammation, Lung Cancer, Lymphoma, Muscular Dystrophy, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Psoriasis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Advanced Malignancy, Atherosclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pre-Diabetes/Impaired Glucose Tolerance, Prostate Cancer, Renal Cell Carcinoma, Retinal Degeneration, Substance (Drug) Abuse, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • ConverGene LLC
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Nuevolution AB
  • Red Glead Discovery AB
  • MORE
Introduction

Report Coverage

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Celgene Corp

Checkpoint Therapeutics Inc

ConverGene LLC

Dybly AG

F. Hoffmann-La Roche Ltd

Forma Therapeutics Inc

GlaxoSmithKline Plc

Kainos Medicine Inc

Mitsubishi Tanabe Pharma Corp

Nuevolution AB

Plexxikon Inc

Red Glead Discovery AB

Resverlogix Corp

Trillium Therapeutics Inc

Zenith Epigenetics Ltd

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles

apabetalone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-581 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-5153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birabresib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-223 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-0610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dBET-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCBD-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DYB-186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-11313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-525762 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-417 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MZ-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-2734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-19796 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NUE-7770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-2853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-51107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6146 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-1301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2535 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit BRD4 for Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Facioscapulohumeral Muscular Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3225 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZBC-260 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEN-3694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones

Featured News & Press Releases

Jun 04, 2018: Zenith Announces Further Advancement of Clinical Trial with ZEN-3694, a Proposed Equity Offering and an Update Webcast

May 24, 2018: Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress

May 07, 2018: Resverlogix Closes US$30 Million Loan

May 01, 2018: Resverlogix Advances US$30 Million Loan Closing Documentation

Apr 18, 2018: Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting

Mar 28, 2018: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease

Mar 26, 2018: Promising drug may stop cancer-causing gene in its tracks

Mar 19, 2018: Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial

Mar 15, 2018: TG Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting

Feb 28, 2018: NEOMED Institute Launches NEOMED Therapeutics 1 to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound

Feb 26, 2018: Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

Feb 09, 2018: Constellation Pharmaceuticals Announces Upcoming Presentations on its Anti-Cancer Drug Candidate CPI-0610

Jan 11, 2018: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase III BETonMACE Trial

Jan 04, 2018: SignalRx Announces In Silico Design And Discovery Of The First-In-Class HDAC6-BRD4-PI3K Epigenetic Kinase Inhibitor SRX3225

Dec 12, 2017: Natures Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent against HIV-1

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by Checkpoint Therapeutics Inc, H1 2018

Pipeline by ConverGene LLC, H1 2018

Pipeline by Dybly AG, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by Forma Therapeutics Inc, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by Kainos Medicine Inc, H1 2018

Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Pipeline by Nuevolution AB, H1 2018

Pipeline by Plexxikon Inc, H1 2018

Pipeline by Red Glead Discovery AB, H1 2018

Pipeline by Resverlogix Corp, H1 2018

Pipeline by Trillium Therapeutics Inc, H1 2018

Pipeline by Zenith Epigenetics Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc
  • Celgene Corp
  • Checkpoint Therapeutics Inc
  • ConverGene LLC
  • Dybly AG
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Mitsubishi Tanabe Pharma Corp
  • Nuevolution AB
  • Plexxikon Inc
  • Red Glead Discovery AB
  • Resverlogix Corp
  • Trillium Therapeutics Inc
  • Zenith Epigenetics Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll